Collins Helen Louise 4

What Happened

• Helen Collins, Chief Medical Officer of Enliven Therapeutics, exercised options and sold the resulting 45,000 shares on February 17, 2026. She exercised the option at $2.48 per share (cost $111,600) and sold the 45,000 shares in the open market at a weighted average price of $26.17 for total gross proceeds of $1,177,862. The net difference before fees and taxes is roughly $1,066,262. The filing also reports the derivative exercise/disposition mechanics associated with the option.

Key Details

• Transaction date: 2026-02-17 (Form 4 filed 2026-02-19 — timely filing).
• Option exercise: 45,000 shares acquired at $2.48 per share (total $111,600).
• Sale: 45,000 shares sold at weighted average $26.17 (range $25.76–$26.695) for $1,177,862 (multiple trades; weighted average reported).
• Shares owned after transaction: not specified in this filing.
• Footnotes: Transactions were executed under a Rule 10b5-1 trading plan adopted Oct 19, 2025; all option shares were fully vested and exercisable as of the date of exercise; seller can provide breakdown of individual trade prices upon request.

Context

• This is an option exercise followed by an immediate sale (a cashless-style outcome): the insider exercised vested options and sold the acquired shares the same day under a pre-established 10b5-1 plan. Such sales under a trading plan are typically pre-planned and do not necessarily indicate a change in the insider’s view of the company.